Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.28
PFE's Cash-to-Debt is ranked lower than
74% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. PFE: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.64 Max: 3.47
Current: 0.28
0.14
3.47
Equity-to-Asset 0.43
PFE's Equity-to-Asset is ranked lower than
78% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.43
0.35
0.66
Debt-to-Equity 0.58
PFE's Debt-to-Equity is ranked lower than
69% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. PFE: 0.58 )
Ranked among companies with meaningful Debt-to-Equity only.
PFE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1  Med: 0.47 Max: 0.79
Current: 0.58
0.1
0.79
Debt-to-EBITDA 1.99
PFE's Debt-to-EBITDA is ranked lower than
56% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. PFE: 1.99 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PFE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.13  Med: 2.03 Max: 2.89
Current: 1.99
1.13
2.89
Interest Coverage 14.85
PFE's Interest Coverage is ranked lower than
71% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. PFE: 14.85 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 9.21  Med: 11.22 Max: 22.47
Current: 14.85
9.21
22.47
Piotroski F-Score: 6
Altman Z-Score: 2.77
Beneish M-Score: -2.25
WACC vs ROIC
7.68%
26.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 26.56
PFE's Operating Margin % is ranked higher than
90% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. PFE: 26.56 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 24.01  Med: 27.03 Max: 31.73
Current: 26.56
24.01
31.73
Net Margin % 41.29
PFE's Net Margin % is ranked higher than
97% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. PFE: 41.29 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 17.03 Max: 42.65
Current: 41.29
12.67
42.65
ROE % 34.08
PFE's ROE % is ranked higher than
95% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. PFE: 34.08 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.28  Med: 12.08 Max: 34.08
Current: 34.08
9.28
34.08
ROA % 12.85
PFE's ROA % is ranked higher than
85% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. PFE: 12.85 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.85
Current: 12.85
4.05
12.85
ROC (Joel Greenblatt) % 97.38
PFE's ROC (Joel Greenblatt) % is ranked higher than
95% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. PFE: 97.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 42  Med: 73.82 Max: 103.79
Current: 97.38
42
103.79
3-Year Revenue Growth Rate 4.00
PFE's 3-Year Revenue Growth Rate is ranked lower than
54% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. PFE: 4.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 6.1 Max: 19.2
Current: 4
-2.5
19.2
3-Year EBITDA Growth Rate 4.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. PFE: 4.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.5  Med: 8.8 Max: 38.4
Current: 4.1
-7.5
38.4
3-Year EPS without NRI Growth Rate 35.70
PFE's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. PFE: 35.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 7.4 Max: 90.5
Current: 35.7
-26.8
90.5
GuruFocus has detected 5 Warning Signs with Pfizer Inc PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2018-08-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

PFE Guru Trades in Q2 2017

Jim Simons 7,990,141 sh (New)
Ray Dalio 183,203 sh (+195.04%)
David Dreman 29,210 sh (+54.54%)
Manning & Napier Advisors, Inc 836,028 sh (+16.21%)
John Buckingham 82,641 sh (+10.80%)
Barrow, Hanley, Mewhinney & Strauss 46,266,431 sh (+8.01%)
Pioneer Investments 9,482,233 sh (+7.21%)
Murray Stahl 73,976 sh (+5.56%)
Richard Pzena 2,332,274 sh (+5.18%)
Ken Fisher 34,035,362 sh (+3.89%)
Jeff Auxier 85,668 sh (+0.94%)
David Carlson 650,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Ronald Muhlenkamp 33,034 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Paul Tudor Jones Sold Out
David Tepper Sold Out
George Soros Sold Out
John Paulson Sold Out
Mairs and Power 4,868,827 sh (-0.05%)
Jeremy Grantham 4,783,377 sh (-0.06%)
Mario Gabelli 484,359 sh (-0.23%)
NWQ Managers 1,262,358 sh (-3.90%)
Diamond Hill Capital 11,331,723 sh (-8.31%)
Kahn Brothers 577,616 sh (-13.48%)
Charles Brandes 5,134,710 sh (-14.68%)
Dodge & Cox 575,228 sh (-15.17%)
T Rowe Price Equity Income Fund 10,237,000 sh (-16.94%)
Lee Ainslie 10,052,571 sh (-49.32%)
Joel Greenblatt 470,928 sh (-50.15%)
» More
Q3 2017

PFE Guru Trades in Q3 2017

Richard Pzena 4,008,274 sh (+71.86%)
Pioneer Investments 10,530,632 sh (+11.06%)
Ken Fisher 35,120,799 sh (+3.19%)
John Buckingham 84,630 sh (+2.41%)
Murray Stahl 74,956 sh (+1.32%)
Manning & Napier Advisors, Inc 838,007 sh (+0.24%)
David Carlson 650,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Dreman 29,210 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Ray Dalio Sold Out
Mario Gabelli 477,126 sh (-1.49%)
Diamond Hill Capital 11,128,596 sh (-1.79%)
Mairs and Power 4,766,771 sh (-2.10%)
Kahn Brothers 557,495 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 44,438,628 sh (-3.95%)
Jeff Auxier 81,068 sh (-5.37%)
T Rowe Price Equity Income Fund 9,565,000 sh (-6.56%)
Dodge & Cox 529,642 sh (-7.92%)
Jeremy Grantham 4,140,797 sh (-13.43%)
NWQ Managers 1,091,151 sh (-13.56%)
Ronald Muhlenkamp 27,494 sh (-16.77%)
Charles Brandes 3,821,667 sh (-25.57%)
Lee Ainslie 7,318,410 sh (-27.20%)
Jim Simons 5,608,741 sh (-29.80%)
Joel Greenblatt 21,817 sh (-95.37%)
» More
Q4 2017

PFE Guru Trades in Q4 2017

First Pacific Advisors 13,000 sh (New)
Steven Cohen 351,897 sh (New)
Tom Russo 1,900 sh (New)
Paul Tudor Jones 25,136 sh (New)
Joel Greenblatt 49,922 sh (+128.82%)
Pioneer Investments 19,093,990 sh (+81.32%)
First Eagle Investment 79,061 sh (+19.68%)
Richard Pzena 4,361,143 sh (+8.80%)
Ken Fisher 36,372,349 sh (+3.56%)
John Buckingham 87,558 sh (+3.46%)
David Carlson 650,000 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Murray Stahl 74,956 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ronald Muhlenkamp 27,494 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Lee Ainslie Sold Out
Kahn Brothers 554,606 sh (-0.52%)
Mairs and Power 4,717,328 sh (-1.04%)
NWQ Managers 1,072,487 sh (-1.71%)
Diamond Hill Capital 10,909,103 sh (-1.97%)
Jeremy Grantham 4,019,297 sh (-2.93%)
Charles Brandes 3,707,279 sh (-2.99%)
Jeff Auxier 78,618 sh (-3.02%)
Barrow, Hanley, Mewhinney & Strauss 42,212,028 sh (-5.01%)
Dodge & Cox 477,331 sh (-9.88%)
T Rowe Price Equity Income Fund 8,520,000 sh (-10.93%)
Mario Gabelli 386,031 sh (-19.09%)
David Dreman 14,424 sh (-50.62%)
Jim Simons 996,641 sh (-82.23%)
» More
Q1 2018

PFE Guru Trades in Q1 2018

Richard Snow 5,752 sh (New)
Ray Dalio 194,322 sh (New)
Joel Greenblatt 1,414,110 sh (+2732.64%)
Robert Bruce 555,332 sh (+21.96%)
Jeremy Grantham 4,282,113 sh (+6.54%)
John Buckingham 91,035 sh (+3.97%)
Ken Fisher 37,773,806 sh (+3.85%)
Mario Gabelli 387,501 sh (+0.38%)
Richard Pzena 4,367,493 sh (+0.15%)
David Carlson 650,000 sh (unchged)
David Dreman 14,424 sh (unchged)
Tom Russo Sold Out
First Pacific Advisors Sold Out
Prem Watsa Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
Jeff Auxier 78,280 sh (-0.43%)
Kahn Brothers 549,944 sh (-0.84%)
Ronald Muhlenkamp 27,239 sh (-0.93%)
Murray Stahl 73,367 sh (-2.12%)
Barrow, Hanley, Mewhinney & Strauss 41,155,163 sh (-2.50%)
T Rowe Price Equity Income Fund 8,290,000 sh (-2.70%)
NWQ Managers 1,035,107 sh (-3.49%)
Charles Brandes 3,501,649 sh (-5.55%)
Dodge & Cox 442,209 sh (-7.36%)
Mairs and Power 4,227,070 sh (-10.39%)
Diamond Hill Capital 9,507,569 sh (-12.85%)
Pioneer Investments 15,324,323 sh (-19.74%)
Eaton Vance Worldwide Health Sciences Fund 1,135,385 sh (-14.50%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -2.50%0.06%$33.63 - $39.02 $ 36.300%41,155,163
Ken Fisher 2018-03-31 Add 3.85%0.07%$33.63 - $39.02 $ 36.300%37,773,806
T Rowe Price Equity Income Fund 2018-03-31 Reduce -2.70%0.04%$33.63 - $39.02 $ 36.300%8,290,000
Richard Pzena 2018-03-31 Add 0.15%$33.63 - $39.02 $ 36.300%4,367,493
Charles Brandes 2018-03-31 Reduce -5.55%0.15%$33.63 - $39.02 $ 36.300%3,501,649
Joel Greenblatt 2018-03-31 Add 2732.64%0.68%$33.63 - $39.02 $ 36.300%1,414,110
NWQ Managers 2018-03-31 Reduce -3.49%0.02%$33.63 - $39.02 $ 36.300%1,035,107
Robert Bruce 2018-03-31 Add 21.96%0.8%$33.63 - $39.02 $ 36.300%555,332
Kahn Brothers 2018-03-31 Reduce -0.84%0.03%$33.63 - $39.02 $ 36.300%549,944
Dodge & Cox 2018-03-31 Reduce -7.36%$33.63 - $39.02 $ 36.300%442,209
Mario Gabelli 2018-03-31 Add 0.38%$33.63 - $39.02 $ 36.300%387,501
Ronald Muhlenkamp 2018-03-31 Reduce -0.93%$33.63 - $39.02 $ 36.300%27,239
Prem Watsa 2018-03-31 Sold Out 0.54%$33.63 - $39.02 $ 36.300%0
First Eagle Investment 2018-03-31 Sold Out 0.01%$33.63 - $39.02 $ 36.300%0
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.01%0.12%$35.06 - $37.2 $ 36.301%42,212,028
Ken Fisher 2017-12-31 Add 3.56%0.06%$35.06 - $37.2 $ 36.301%36,372,349
T Rowe Price Equity Income Fund 2017-12-31 Reduce -10.93%0.18%$35.06 - $37.2 $ 36.301%8,520,000
Richard Pzena 2017-12-31 Add 8.80%0.06%$35.06 - $37.2 $ 36.301%4,361,143
Charles Brandes 2017-12-31 Reduce -2.99%0.08%$35.06 - $37.2 $ 36.301%3,707,279
NWQ Managers 2017-12-31 Reduce -1.71%0.01%$35.06 - $37.2 $ 36.301%1,072,487
Kahn Brothers 2017-12-31 Reduce -0.52%0.02%$35.06 - $37.2 $ 36.301%554,606
Dodge & Cox 2017-12-31 Reduce -9.88%$35.06 - $37.2 $ 36.301%477,331
Mario Gabelli 2017-12-31 Reduce -19.09%0.02%$35.06 - $37.2 $ 36.301%386,031
First Eagle Investment 2017-12-31 Add 19.68%$35.06 - $37.2 $ 36.301%79,061
Joel Greenblatt 2017-12-31 Add 128.82%0.02%$35.06 - $37.2 $ 36.301%49,922
David Dreman 2017-12-31 Reduce -50.62%0.29%$35.06 - $37.2 $ 36.301%14,424
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -3.95%0.09%$32.67 - $35.99 $ 36.307%44,438,628
Ken Fisher 2017-09-30 Add 3.19%0.06%$32.67 - $35.99 $ 36.307%35,120,799
T Rowe Price Equity Income Fund 2017-09-30 Reduce -6.56%0.11%$32.67 - $35.99 $ 36.307%9,565,000
Richard Pzena 2017-09-30 Add 71.86%0.32%$32.67 - $35.99 $ 36.307%4,008,274
Charles Brandes 2017-09-30 Reduce -25.57%0.7%$32.67 - $35.99 $ 36.307%3,821,667
NWQ Managers 2017-09-30 Reduce -13.56%0.08%$32.67 - $35.99 $ 36.307%1,091,151
Kahn Brothers 2017-09-30 Reduce -3.48%0.1%$32.67 - $35.99 $ 36.307%557,495
Dodge & Cox 2017-09-30 Reduce -7.92%$32.67 - $35.99 $ 36.307%529,642
Mario Gabelli 2017-09-30 Reduce -1.49%$32.67 - $35.99 $ 36.307%477,126
Ronald Muhlenkamp 2017-09-30 Reduce -16.77%0.06%$32.67 - $35.99 $ 36.307%27,494
Joel Greenblatt 2017-09-30 Reduce -95.37%0.21%$32.67 - $35.99 $ 36.307%21,817
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 8.01%0.18%$31.75 - $34.34 $ 36.309%46,266,431
Ken Fisher 2017-06-30 Add 3.89%0.07%$31.75 - $34.34 $ 36.309%34,035,362
T Rowe Price Equity Income Fund 2017-06-30 Reduce -16.94%0.33%$31.75 - $34.34 $ 36.309%10,237,000
Charles Brandes 2017-06-30 Reduce -14.68%0.45%$31.75 - $34.34 $ 36.309%5,134,710
Richard Pzena 2017-06-30 Add 5.18%0.02%$31.75 - $34.34 $ 36.309%2,332,274
NWQ Managers 2017-06-30 Reduce -3.90%0.02%$31.75 - $34.34 $ 36.309%1,262,358
Kahn Brothers 2017-06-30 Reduce -13.48%0.53%$31.75 - $34.34 $ 36.309%577,616
Dodge & Cox 2017-06-30 Reduce -15.17%$31.75 - $34.34 $ 36.309%575,228
Mario Gabelli 2017-06-30 Reduce -0.23%$31.75 - $34.34 $ 36.309%484,359
Joel Greenblatt 2017-06-30 Reduce -50.15%0.21%$31.75 - $34.34 $ 36.309%470,928
David Dreman 2017-06-30 Add 54.54%0.19%$31.75 - $34.34 $ 36.309%29,210
George Soros 2017-06-30 Sold Out 0.03%$31.75 - $34.34 $ 36.309%0
David Tepper 2017-06-30 Sold Out 1.7%$31.75 - $34.34 $ 36.309%0
John Paulson 2017-06-30 Sold Out 0.19%$31.75 - $34.34 $ 36.309%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XSWX:ROG, XSWX:NOVN, NYSE:MRK, NYSE:ABBV, XTER:BAYN, LSE:GSK, XPAR:SAN, NYSE:JNJ, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867 » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing close to 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
Regulator Approves Pfizer Drug for US Patients The drug will be used in the US for treatment of anemia
Pfizer Inc. (NYSE:PFE) has informed the market that it received the U.S. Food and Drug Administration’s approval for a drug it has developed to treat anemia resulting from chemotherapy or chronic kidney disease. Read more...
Dow Jones Reports 8th Consecutive Positive Close US market indexes begin the week with gains
U.S. market indexes closed higher on Monday. The Dow Jones Industrial Average closed at 24899.41 for a gain of 68.24 points or 0.27%. The S&P 500 closed at 2730.13 for a gain of 2.41 points or 0.09%. The Nasdaq Composite closed at 7411.32 for a gain of 8.43 points or 0.11%. The VIX Volatility Index closed at 12.93 with a gain of 0.28 points or 2.21%. Read more...
Francis Chou Plunges Into Valeant and Endo in 1st Quarter Valeant CEO gives strong restructuring initiatives
Francis Chou (Trades, Portfolio), portfolio manager of Chou America Mutual Funds, disclosed he expanded his positions in Valeant Pharmaceuticals International Inc. (NYSE:VRX) and Endo International PLC (NASDAQ:ENDP) during the first quarter. Read more...
Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer
Is now the time to buy, sell, or hold Apple, Advanced Micro Devices, Pfizer, Tenet Healthcare, or Tapestry?
Wall Street Trades in Negative Territory on Tuesday Cognex revenue miss estimates
U.S. stock markets reversed their trend and traded in negative ground Tuesday morning. Read more...
Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco — Future Expectations, Projections Moving into 2018
Esperion Could Surge If Its Cholesterol Drug Proves Safe Esperion Therapeutics has a potential blockbuster cholesterol drug in Phase III with fewer side effects than statins, but it has to be tested on many more people
Cholesterol-reducing statins may be one of the most prescribed, lucrative and successful drug classes in the world, but many people just can’t tolerate them. They cause muscle pain for many, or myalgia (think induced fibromyalgia) because, while they are meant to target chemical intermediaries of cholesterol synthesis in the liver, they also affect intermediaries that promote muscle cell function. Many patients who need these drugs to survive can’t take them. But only 55% of people keep taking statins after six months. Some of this is due to laziness, but side effects are responsible for about 30% of the stoppages overall. Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.08
PFE's PE Ratio is ranked higher than
92% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. PFE: 10.08 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 17.06 Max: 34.43
Current: 10.08
7.68
34.43
Forward PE Ratio 12.36
PFE's Forward PE Ratio is ranked higher than
80% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. PFE: 12.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.08
PFE's PE Ratio without NRI is ranked higher than
92% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. PFE: 10.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.58  Med: 19.65 Max: 34.43
Current: 10.08
9.58
34.43
Price-to-Owner-Earnings 8.70
PFE's Price-to-Owner-Earnings is ranked higher than
91% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.72 vs. PFE: 8.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.92 Max: 36.49
Current: 8.7
5.44
36.49
PB Ratio 3.08
PFE's PB Ratio is ranked lower than
52% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. PFE: 3.08 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.42 Max: 3.57
Current: 3.08
1.32
3.57
PS Ratio 4.17
PFE's PS Ratio is ranked lower than
60% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. PFE: 4.17 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.64 Max: 4.74
Current: 4.17
1.72
4.74
Price-to-Free-Cash-Flow 15.01
PFE's Price-to-Free-Cash-Flow is ranked higher than
72% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. PFE: 15.01 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.64 Max: 18.91
Current: 15.01
5.02
18.91
Price-to-Operating-Cash-Flow 13.02
PFE's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. PFE: 13.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 12.07 Max: 15.89
Current: 13.02
4.55
15.89
EV-to-EBIT 16.95
PFE's EV-to-EBIT is ranked higher than
57% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. PFE: 16.95 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.9  Med: 14.4 Max: 21.7
Current: 16.95
6.9
21.7
EV-to-EBITDA 11.77
PFE's EV-to-EBITDA is ranked higher than
69% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. PFE: 11.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 9.3 Max: 14.4
Current: 11.77
5
14.4
EV-to-Revenue 4.60
PFE's EV-to-Revenue is ranked lower than
62% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. PFE: 4.60 )
Ranked among companies with meaningful EV-to-Revenue only.
PFE' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.7 Max: 5
Current: 4.6
1.6
5
PEG Ratio 4.39
PFE's PEG Ratio is ranked lower than
77% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. PFE: 4.39 )
Ranked among companies with meaningful PEG Ratio only.
PFE' s PEG Ratio Range Over the Past 10 Years
Min: 2.14  Med: 5.31 Max: 46.14
Current: 4.39
2.14
46.14
Shiller PE Ratio 19.53
PFE's Shiller PE Ratio is ranked higher than
78% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. PFE: 19.53 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.12  Med: 16.79 Max: 21.94
Current: 19.53
9.12
21.94
Current Ratio 1.27
PFE's Current Ratio is ranked lower than
79% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. PFE: 1.27 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.5 Max: 3.18
Current: 1.27
0.98
3.18
Quick Ratio 0.98
PFE's Quick Ratio is ranked lower than
73% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. PFE: 0.98 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.22 Max: 2.86
Current: 0.98
0.74
2.86
Days Inventory 248.96
PFE's Days Inventory is ranked lower than
89% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. PFE: 248.96 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 211.62  Med: 233.12 Max: 344.63
Current: 248.96
211.62
344.63
Days Sales Outstanding 65.50
PFE's Days Sales Outstanding is ranked higher than
67% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. PFE: 65.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 66.96 Max: 106.89
Current: 65.5
56.83
106.89
Days Payable 124.93
PFE's Days Payable is ranked higher than
82% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. PFE: 124.93 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 78.79  Med: 122.74 Max: 179.46
Current: 124.93
78.79
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.65
PFE's Dividend Yield % is ranked higher than
86% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. PFE: 3.65 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.67 Max: 10.4
Current: 3.65
2.9
10.4
Dividend Payout Ratio 0.36
PFE's Dividend Payout Ratio is ranked higher than
77% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. PFE: 0.36 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.74 Max: 1.08
Current: 0.36
0.36
1.08
3-Year Dividend Growth Rate 7.20
PFE's 3-Year Dividend Growth Rate is ranked higher than
52% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. PFE: 7.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.2
-14.7
22.6
Forward Dividend Yield % 3.73
PFE's Forward Dividend Yield % is ranked higher than
87% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.73 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.31
PFE's 5-Year Yield-on-Cost % is ranked higher than
89% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. PFE: 5.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.22  Med: 5.34 Max: 15.14
Current: 5.31
4.22
15.14
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.2 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.13
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. PFE: 1.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.15 Max: 9.98
Current: 1.13
0.53
9.98
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.90
PFE's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
75% of the 87 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.52 vs. PFE: 0.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
PFE' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.86  Med: 1.79 Max: 13.13
Current: 0.9
0.86
13.13
Price-to-Median-PS-Value 1.15
PFE's Price-to-Median-PS-Value is ranked lower than
58% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. PFE: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.44  Med: 1.07 Max: 3.27
Current: 1.15
0.44
3.27
Earnings Yield (Greenblatt) % 5.90
PFE's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. PFE: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.6  Med: 6.9 Max: 14.5
Current: 5.9
4.6
14.5
Forward Rate of Return (Yacktman) % 7.90
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. PFE: 7.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.8  Med: 10.6 Max: 15.3
Current: 7.9
5.8
15.3

More Statistics

Revenue (TTM) (Mil) $52,673.00
EPS (TTM) $ 3.60
Beta0.93
Volatility9.14%
52-Week Range $32.32 - 39.43
Shares Outstanding (Mil)5,849.57

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 54,316 55,532 55,413
EBIT (Mil $) 19,896 20,923 21,776
EBITDA (Mil $) 23,701 24,653 24,747
EPS ($) 2.20 2.42 2.62
EPS without NRI ($) 2.20 2.42 2.62
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.04%
Dividends per Share ($) 1.38 1.47 1.52

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}